Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Plans to Raise up to $2.5 Billion in Shanghai Star IPO

publication date: Nov 17, 2020

BeiGene (NSDQ: BGNE; HK: 06160) is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. The Beijing company is already listed in Hong Kong and the US, and it raised $2.1 billion in a secondary offering on the Hong Exchange in July of this year. Now ten years old, BeiGene is spending big to conduct clinical trials for drug approvals and additional indications for its products. At the end of Q3, the company has $4.7 billion of cash in hand, but it lost $560 million in the first nine months of 2020 on revenues totaling $371 million. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China